Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Italfarmaco S.p.A.
Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.
The Jennifer Doudna-backed startup got a billion-dollar valuation with VC rounds totaling $195m. CEO Trevor Martin talked with Scrip about Mammoth’s ultra-small CRISPR system technology.
Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m.
Tempest goes public via a reverse merger with Millendo. Takeda inks its ninth deal of 2021, a discovery pact with BridGene around its chemoproteomics technology.
- Drug Delivery
- Other Names / Subsidiaries
- ITF Pharma SpA, CHEMI S.P.A